"Akums Signs €200 Million Deal with Global Pharma Company for European Market"

Akums Group has secured a long-term agreement with a global pharmaceutical company to manufacture and supply formulations for the European market. The total value of the agreement is estimated at €200 million (₹1,760 crore), with Akums set to receive an upfront payment of €100 million (₹880 crore) for product development and site approval from European authorities.

As a contract manufacturing and development organization (CDMO), Akums will produce a range of oral liquid formulations, which its partner will market across multiple European countries. This partnership is part of Akums' strategy to expand its presence in Europe and other regulated markets, alongside strengthening local manufacturing capabilities.

The commercial supply of these products is expected to begin in 2027, continuing through to 2032. As part of the agreement, Akums will initiate the approval process for its oral liquid manufacturing facility, with product and site dossier approvals anticipated by the end of 2026. Akums already operates two European-approved facilities for injectables and oral solids.

Sanjeev Jain, Managing Director of Akums, emphasized that the agreement presents a significant opportunity for global expansion, noting, “This deal allows us to replicate our domestic CDMO success internationally. Manufacturing these products in India opens further collaboration opportunities with global pharma companies to optimize costs and enhance supply chain resilience."

Akums already has several European-approved facilities for a wide range of products, including tablets, capsules, eye drops, and injections, solidifying its position as a key player in the global pharmaceutical manufacturing landscape.

HBL